No Data
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $16
Cogent Biosciences: Promising Pipeline and Strategic Positioning Drive Buy Rating
Express News | Cogent Biosciences Announces Pipeline Expansion Into Kras and Poster Presentations at the 2024 Eortc-Nci-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Cogent Biosciences Announces Pipeline Expansion Into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
No Data
No Data